About Lentigen
Lentigen is a company based in Gaithersburg (United States) founded in 2004 was acquired by Miltenyi Biotec in August 2014. Lentigen has completed 1 acquisition, including Living Pharma. Lentigen operates in a competitive market with competitors including StrideBio, LogicBio, Phase Genomics, Candel Therapeutics and Sixfold Bioscience, among others.
- Headquarter Gaithersburg, United States
-
Sectors
Healthcare
-
Phone
Locked
-
Website
Locked
-
Social
Locked
-
Annual Revenue
Not available
-
Net Profit
Not available
-
EBITDA
Not available
-
Latest Funding Round
$1.2 M (USD), Grant
Nov 04, 2010
-
Investors
Miltenyi Biotec
& 1 more
-
Employee Count
Not available
- Investments & Acquisitions
-
Acquired by
Miltenyi Biotec
(Aug 14, 2014)
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Funding Insights of Lentigen
Investors in Lentigen
Lentigen has secured backing from 2 investors, including institutional investors. Prominent investors backing the company include Miltenyi Biotec and HHS.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Public health and human services are overseen by HHS.
|
Locked | Locked | Locked | |
|
Develops tools and products for research and clinical application
|
Locked | Locked | Locked |
Investor details for Lentigen
Investor domains, locations, round participation, and complete history require an active premium plan.
- Investor domains
- Investor locations
- Funding rounds
- Participation history
Verified entity values are shown only after access is granted.
Investments & Acquisitions by Lentigen
Lentigen has strategically engaged in corporate development activities, having acquired 1 company. Notable acquisitions include Living Pharma.
Investment portfolio details for Lentigen
Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.
- Portfolio identities
- Transaction dates
- Round details
- Investment values
Verified entity values are shown only after access is granted.
| Company Name | Description | Domain | Location | Founded Year | Amount |
|---|---|---|---|---|---|
|
Personalized anti-tag CAR T cell therapies for cancer are developed.
|
Locked | Locked | 2015 | Locked |
Complete acquisition details for Lentigen
Transaction dates, acquired stakes, disclosed values, domains, and locations require an active premium plan.
- Transaction dates
- Acquired stakes
- Disclosed values
- Domains and locations
Verified entity values are shown only after access is granted.
Financial Statements - Lentigen
Detailed financials for Lentigen
Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.
- Historical revenue
- Profit trends
- Statement rows
- Financial ratios
Verified entity values are shown only after access is granted.
Lentigen Comparisons
Peer comparison for Lentigen
Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.
- Named peers
- Headcount comparison
- Funding comparison
- Operating benchmarks
Verified entity values are shown only after access is granted.
Competitors of Lentigen
Lentigen operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as StrideBio, LogicBio, Phase Genomics, Candel Therapeutics and Sixfold Bioscience, among others.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| Locked | Locked | Locked |
AAV-based gene therapies for rare diseases are developed.
|
|
| Locked | Locked | Locked |
Viral vectors are developed for genetic and infectious disease treatments.
|
|
| Locked | Locked | Locked |
Laboratory and computational services for DNA proximity analysis are provided.
|
|
| Locked | Locked | Locked |
Viral immunotherapies are developed for cancer treatment.
|
|
| Locked | Locked | Locked |
Oligonucleotide delivery systems are developed for targeted gene therapy.
|
|
| Locked | Locked | Locked |
Genetic medicines are delivered using polymer nanoparticle platforms.
|
Detailed competitors of Lentigen
Competitor domains, locations, full profiles, and operating metrics require an active premium plan.
- Domains and locations
- Full company profiles
- Operating metrics
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Lentigen
Complete news archive for Lentigen
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Lentigen
Lentigen was founded in 2004 and raised its 1st funding round 1 year after it was founded.
Lentigen is headquartered in Gaithersburg, United States. It is registered at Gaithersburg, Maryland, United States.
Lentigen was founded in 2004 in Gaithersburg, United States, focusing on the biotechnology sector. Lentiviral vectors are manufactured for translational research, including multi-lentiviral vector evaluation for construct assessment, custom concentrated vectors for feasibility studies, and chromatography-purified vectors for process evaluation. Operations support pre-clinical and clinical applications in gene therapy and related fields.
Lentigen's top competitors include Phase Genomics, Genedit and CellFE.
Lentigen has made 1 acquisition, including Living Pharma.
Lentigen has 2 investors. Key investors include Miltenyi Biotec, and HHS.